Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elexacaftor/ivacaftor/tezacaftor + ivacaftor - Vertex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Elexacaftor/ivacaftor/tezacaftor + ivacaftor - Vertex Pharmaceuticals

Alternative Names: Elexacaftor/ivacaftor/tezacaftor - Vertex Pharmaceuticals; ELX/TEZ/IVA; Ivacaftor/tezacaftor/VX 445; Kaftrio; Tezacaftor/VX-445/ivacaftor; TRIKAFTA; TRIKAFTA®; VX 445/ivacaftor/tezacaftor; VX-445/TEZ/IVA; VX-445/VX-661/VX-770

Latest Information Update: 18 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Antifibrotics; Benzodioxoles; Cyclopropanes; Fluorinated hydrocarbons; Fluorobenzenes; Indoles; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Small molecules; Sulfonamides
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis

Most Recent Events

  • 15 Jul 2024 Registered for Cystic fibrosis (In adolescents, In children, In the elderly, In adults) in Canada (PO)
  • 18 Jun 2024 Vertex Pharmaceuticals plans a phase III trial for Cystic-fibrosis (In adolesecents, In adults, In the elderly) (PO, Granules) in October 2024 (NCT06460506) (EudraCT2023-509563-24-00)
  • 10 Jun 2024 Adverse events and efficacy data from a phase-III trial in Cystic fibrosis released by Vertex Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top